메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Takayoshi Nakamura (Graduate School of Medicine Institute for Genetic Medicine Hokkaido University Sapporo Japan) Nabeel Kajihara (Graduate School of Medicine Institute for Genetic Medicine Hokkaido University Sapporo Japan) Naoki Hama (Graduate School of Medicine Institute for Genetic Medicine Hokkaido University Sapporo Japan) Takuto Kobayashi (Graduate School of Medicine Institute for Genetic Medicine Hokkaido University Sapporo Japan) Ryo Otsuka (Graduate School of Medicine Institute for Genetic Medicine Hokkaido University Sapporo Japan) Nanumi Han (Graduate School of Medicine Institute for Genetic Medicine Hokkaido University Sapporo Japan) Haruka Wada (Graduate School of Medicine Institute for Genetic Medicine Hokkaido University Sapporo Japan) Yoshinori Hasegawa (Kazusa DNA Research Institute Kisarazu Japan) Nao Suzuki (St. Marianna University School of Medicine) Ken-ichiro Seino (Graduate School of Medicine Institute for Genetic Medicine Hokkaido University Sapporo Japan)
저널정보
대한부인종양학회 Journal of Gynecologic Oncology Journal of Gynecologic Oncology Vol.34 No.3
발행연도
2023.5
수록면
1 - 16 (16page)
DOI
10.3802/jgo.2023.34.e25

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Objective: Breast cancer susceptibility gene 1 (BRCA1)-associated ovarian cancer patients havebeen treated with A poly (ADP-ribose) polymerase (PARP) inhibitor, extending the progression-free sur vival; however, they finally acquire therapeutic resistance. Interleukin (IL)-34 hasbeen reported as a poor prognostic factor in several cancers, including ovarian cancer, and itcontributes to the therapeutic resistance of chemotherapies. IL-34 may affect the therapeuticeffect of PARP inhibitor through the regulation of tumor microenvironment (TME). Methods: In this study, The Cancer Genome Atlas (TCGA) data set was used to evaluate theprognosis of IL-34 and human ovarian serous carcinoma. We also used CRISPR-Cas9 genomeediting technology in a mouse model to evaluate the efficacy of PARP inhibitor therapy in thepresence or absence of IL-34. Results: We found that IL34 was an independent poor prognostic factor in ovarian serouscarcinoma, and its high expression significantly shortens overall sur vival. Furthermore,in BRCA1-associated ovarian cancer, PARP inhibitor therapy contributes to anti-tumorimmunity via the XCR1+ DC-CD8+ T cell axis, however, it is canceled by the presence of IL-34. Conclusion: These results suggest that tumor-derived IL-34 benefits tumors by creating animmunosuppressive TME and conferring PARP inhibitor therapeutic resistance. Thus, we showedthe pathological effect of IL-34 and the need for it as a therapeutic target in ovarian cancer.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0